Company intelligence / Profile preview
SCOHIA PHARMA, Inc.
Fujisawa, Kanagawa, Japanscohia.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
The company has multiple programs in development, with its lead candidate Imarikiren hydrochloride (renin inhibitor) in Phase 2 for diabetic nephropathy. SCO-240 (SSTR5 antagonist) and SCO-267 (GPR40 agonist) are in Phase 1 trials for infertility/growth hormone disorders and obesity, respectively. Several preclinical programs are also in development.
- Therapeutic areas
- Women's HealthEndocrinologyCardiovascularNephrology
- Modalities
- Small molecule drugsSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Takeda Pharmaceutical Company LimitedMEDIPAL Holdings Corporation
Beyond the preview
Go deeper on SCOHIA PHARMA, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCOHIA PHARMA, Inc..